Latanoprost Aurobindo (Latanoprost)

Latanoprost binds to FP receptors in the eye’s ciliary body, triggering remodeling of the extracellular matrix. This enhances the uveoscleral outflow pathway, allowing aqueous humor to drain more efficiently and thereby reducing intra‑ocular pressure.

The dosing regimen for Latanoprost Aurobindo is determined by the prescribing clinician. Typically, a single drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and a strong IOP‑lowering effect. Compared with beta‑blocker drops, it often provides greater pressure reduction with fewer systemic side effects, though it may cause ocular changes such as iris darkening.

Store Latanoprost Aurobindo at room temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from light, and avoid exposure to moisture. Do not freeze the product.

Latanoprost Aurobindo is administered as a single drop into the conjunctival sac of the affected eye(s) once daily, usually in the evening. Patients should wash their hands before use, avoid touching the tip of the bottle to any surface, and follow any additional instructions from their eye‑care professional.

Serious risks, though rare, include severe eye inflammation (uveitis or iritis), allergic reactions such as swelling or rash, sudden vision loss, and corneal edema. Patients should seek immediate medical attention if they experience any of these symptoms.

Latanoprost Aurobindo should be avoided in patients with active ocular infections, known hypersensitivity to latanoprost or any component of the formulation, and in individuals who have had recent ocular surgery unless cleared by the surgeon. Contraindications should be confirmed by the prescribing clinician.